SLNO
Soleno Therapeutics Inc.
$57.08
+$0.50(+0.87%)
72
Overall
--
Value
72
Tech
--
Quality
Market Cap
$2.91B
Volume
1.17M
52W Range
$41.50 - $90.32
Target Price
$119.60
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $607.5K | $1.5M | -- | -- | $173.0K | -- | -- | -- | -- | -- | ||
| Total Revenue | $387.6K | $1.5M | -- | -- | $173.0K | -- | -- | -- | -- | -- | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-352.7K | $-1.5M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $254.8K | $-58.5K | -- | -- | $173.0K | -- | -- | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-12.4M | $-8.3M | $-12.2M | $-14.3M | $-23.5M | $36.3M | $31.5M | $25.1M | $41.4M | $187.7M | ||
| Research & Development | $4.5M | $2.2M | $3.1M | $7.2M | $16.3M | $23.2M | $21.5M | $15.3M | $25.2M | $78.6M | ||
| Research Expense | $4.5M | $2.2M | $3.1M | $7.2M | $16.3M | $23.2M | $21.5M | $15.3M | $25.2M | $78.6M | ||
| Selling, General & Administrative | $7.9M | $6.1M | $6.6M | $6.6M | $6.9M | $8.8M | $10.8M | $9.8M | $13.5M | $105.9M | ||
| Selling & Marketing Expenses | $1.7M | $1.6M | $26.0K | -- | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $6.1M | $6.1M | $6.6M | $6.6M | $6.9M | $8.8M | $10.8M | $9.8M | $13.5M | $105.9M | ||
| Salaries & Wages | $-942.4K | $-871.3K | $-1.0M | $-1.3M | $-825.0K | -- | -- | $2.5M | $5.9M | $100.0M | ||
| Depreciation & Amortization | $-67.4K | $-33.3K | $-44.0K | $-19.0K | $-11.0K | $11.0K | $19.0K | $20.0K | $2.0M | $2.0M | ||
| Depreciation & Amortization | $-67.4K | $-33.3K | $-44.0K | $-19.0K | $-11.0K | $11.0K | $19.0K | $20.0K | $2.0M | $2.0M | ||
| Amortization | $-40.8K | $-99.3K | $-1.7M | $-1.9M | $-1.9M | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M | ||
| Other Operating Expenses | $-31.7K | $8.3M | $2.5M | $567.0K | $289.0K | $-4.3M | $731.0K | $-379.0K | $-1.0M | $-2.9M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-12.2M | $-16.6M | $-12.2M | $-14.3M | $-23.5M | $-36.3M | $-31.5M | $-24.4M | $-41.4M | $-187.7M | ||
| EBITDA | $-15.8M | $-6.7M | $-11.8M | $-9.9M | $-28.8M | $-30.0M | $-30.3M | $-22.6M | $-37.5M | $-174.9M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | $-1.0K | $2.0K | -- | -- | -- | -- | ||
| Intinc | -- | -- | $-1.3M | $-160.0K | $-478.0K | -- | -- | -- | $2.6M | $12.1M | ||
| Net Non-Operating Interest Income/Expense | -- | -- | $-1.3M | $-160.0K | $-478.0K | $-2.0K | -- | $-300.0K | $2.6M | $12.1M | ||
| Gain on Sale of Securities | -- | -- | -- | $2.0M | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $515.9K | $-1.6M | $1.3M | $-2.6M | $6.8M | $-11.7M | $-618.0K | $742.0K | $182.0K | $-11.8M | ||
| Other Special Charges | $-515.9K | $1.6M | $-1.3M | $626.0K | $-6.8M | $11.7M | $618.0K | $330.0K | $-182.0K | $11.8M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | $-183.6K | $13.1K | $-590.1K | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-15.9M | $-6.7M | $-13.4M | $-11.8M | $-30.8M | $-31.9M | $-32.3M | $-24.6M | $-39.5M | $-176.9M | ||
| Pre-Tax Income | $-15.9M | $-6.7M | $-13.4M | $-11.8M | $-30.8M | $-16.0M | $-32.4M | $-24.1M | $-36.3M | $-175.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-705.3K | $-511.9K | $-1.6M | $-456.0K | $-1.0K | $-2.3M | $-2.3M | $-527.0K | $-505.0K | $-1.1M | ||
| NET INCOME | ||||||||||||
| Net Income | $-12.9M | $-20.4M | $-15.4M | $-11.8M | $-30.8M | $-24.6M | $-30.9M | $-24.1M | $-39.0M | $-175.8M | ||
| Net Income (Continuing Operations) | $-12.9M | $-20.4M | $-15.4M | $-11.8M | $-30.8M | $-24.6M | $-30.9M | $-24.1M | $-39.0M | $-175.8M | ||
| Net Income (Discontinued Operations) | $-12.9M | $-20.4M | $-15.4M | $-11.8M | $-30.8M | $-24.6M | $-30.9M | $-24.1M | $-39.0M | $-175.8M | ||
| Net Income (Common Stockholders) | $-15.9M | $-24.0M | $-15.4M | $-11.8M | $-30.8M | $-24.6M | $-30.9M | $-24.1M | $-39.0M | $-175.8M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-34.7M | -- | -- | $-173.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-12.8M | $-8.3M | $-12.2M | $-14.3M | $-23.5M | $36.3M | $31.5M | $25.1M | $41.4M | $187.7M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $628.4K | $1.0M | $598.5K | $1.4M | $2.3M | $4.2M | $5.3M | $8.4M | $16.5M | $40.2M | ||
| Average Shares Outstanding (Diluted) | $507.3K | $796.4K | $1.1M | -- | -- | $4.2M | $5.3M | $8.4M | $16.5M | $40.2M | ||
| Shares Outstanding | $205.4K | $633.1K | $1.3M | $2.1M | $3.0M | $5.3M | $5.3M | $8.2M | $32.5M | $45.9M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-5.85 | $-5.85 | $-2.87 | $-2.36 | $-4.38 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-5.85 | $-5.85 | $-2.87 | $-2.36 | $-4.38 | ||
| Diluted EPS | $-25.35 | $-15.15 | $-26.25 | -- | -- | $-5.85 | $-5.85 | $-2.87 | $-2.36 | $-4.38 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-2.87 | $-2.36 | $-4.38 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | $3.0M | $3.7M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Diluted Discontinuous Operations | -- | -- | $-6 | $-1.05 | -- | -- | -- | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | $-5.3M | $-3.4M | $-1.5M | -- | -- | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | -- | $-5.3M | $-3.6M | $-1.5M | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | $183.6K | $-13.1K | $590.1K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | $-194.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $6.1M | $6.1M | $6.6M | $6.6M | $6.9M | $8.8M | $10.8M | $9.8M | $13.5M | $105.9M | ||
| Otherunder Preferred Stock Dividend | $3.0M | $3.7M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $3.0M | $3.7M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $6.1M | $6.1M | $6.6M | $6.6M | $6.9M | -- | -- | -- | -- | -- | ||
| Selling Expense | $1.7M | $1.6M | $26.0K | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLNO | $57.08 | +0.9% | 1.17M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Soleno Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW